OncLive TV

Zosia Piotrowska, MD, Christine Lovly, MD, PhD, and Amanda Cass, PharmD, BCPS, BCOP, discuss the management of paronychia when treating patients with EGFR TKIs.

Gregory Riely, MD, and Shirish Gadgeel, MD, discuss how to address cardiac-related toxicities associated with treatment with EGFR TKIs.

Zosia Piotrowska, MD, Christine Lovly, MD, PhD, and Amanda Cass, PharmD, BCPS, BCOP, discuss the safety profile of mobocertinib in EGFR exon 20 insertion mutation–positive advanced non–small cell lung cancer.

Joshua Brody, MD, discusses key follow-up data from the phase 3 ECHELON-1 trial in classical Hodgkin lymphoma.

Stephen V. Liu, MD, discusses efforts to develop atezolizumab-based combination therapies for patients with small cell lung cancer.

Zosia Piotrowska, MD, Christine Lovly, MD, PhD, and Amanda Cass, PharmD, BCPS, BCOP discuss common adverse effects with EGFR TKIs.

Jeanne G. Vaughn, NP, Kristina Lo, PharmD, BCOP, Jonathan Riess, MD, MS, and Ticiana Leal, MD, discuss the impact of skin toxicities when utilizing EGFR TKIs.

Christine Lovly, MD, PhD, Jeanne G. Vaughn, NP, Kristina Lo, PharmD, BCOP, and Linda Ahn discuss how to approach treatment-related adverse effects of the skin and mouth associated with the use of EGFR TKIs.

Nirav N. Shah, MD, discusses remaining unmet needs with CAR T-cell therapies, and how to ameliorate these challenges for patients with hematologic malignancies.

John O. Mascarenhas, MD, discusses current advancement in the treatment landscape of myelofibrosis.

Erika P. Hamilton, MD, discusses previously reported and anticipated findings from the DESTINY-Breast03 trial, which compared the efficacy of 2 antibody-drug conjugates, fam-trastuzumab deruxtecan-nxki and ado-trastuzumab emtansine, in patients with HER2-positive metastatic breast cancer.

Craig Moskowitz, MD, discusses the efficacy of several antibody-drug conjugates in diffuse large B-cell lymphoma, how their adverse effect profiles compare, and how bispecific antibodies are further defining the DLBCL treatment landscape.

Elias Jabbour, MD, discusses the importance of testing for minimal residual disease when determining optimal treatment strategies for patients with B-cell acute lymphoblastic leukemia.

Peter R. Dottino, MD, discusses the benefit of early-detection screening for endometrial cancer.

Rana R. McKay, MD, discusses the pros and cons of utilizing triplet therapy in the frontline treatment of patients with renal cell carcinoma.

Raajit K. Rampal, MD, PhD, discusses the future research of CDK4/6 inhibitors in myeloproliferative neoplasms.

Eric Jonasch, MD, discusses the promise of the hypoxia inducible factor-2 alpha inhibitor belzutifan in metastatic renal cell carcinoma.

Ritu Salani, MD, MBA, discusses the role of HER2 expression on treatment decisions in advanced uterine serous carcinomas.

Murali Janakiram, MD, MS, discusses future targets and research strategies for CAR T-cell therapy in multiple myeloma.

Wade T. Iams, MD, discusses the rationale of targeting the LAG-3 pathway in patients with advanced non­–small cell lung cancer.

Eunice Wang, MD, discusses the current treatment options for blastic plasmacytoid dendritic cell neoplasm.

Sara A. Hurvitz, MD, discusses the evolution of targeted therapies in HER2-positive breast cancer.

Raajit K. Rampal, MD, PhD, discusses the investigation of pelabresib with or without ruxolitinib in patients with myelofibrosis.

Jason Romancik, MD, discusses the benefit of axicabtagene ciloleucel vs standard of care as a second-line treatment for patients with relapsed/refractory diffuse large B-cell lymphoma.

Alexander Drilon, MD, discusses the significance of the FDA approval of selpercatinib in RET fusion–positive solid tumors.

Praveen Ramakrishnan, MD, MS, discusses the evolving landscape of CAR T-cell therapy in diffuse large B-cell lymphoma.

Alison K. Conlin, MD, discusses the benefits of trastuzumab deruxtecan in HER2-low breast cancer.

Richard J. Lin, MD, PhD, discusses the manufacturing considerations that factor into the CAR T-cell decision-making process in diffuse large B-cell lymphoma, the importance of open communication between community and referral physicians, and how early referral leads to optimal patient outcomes with CAR T-cell therapy.

Jason Westin, MD, FACP, discusses reasons to refer patients with diffuse large B-cell lymphoma to second-line CAR T-cell therapy, CAR T-cell eligibility criteria, and high-risk disease features that may further support the use of CAR T-cell therapy in the second line, rather than chemotherapy.

Rana R. McKay, MD, discusses the potential impact of triplet therapies in the treatment paradigm for metastatic renal cell carcinoma and identifies several other areas for further study.